S-1: Veterinary Operator Seeks Capital Amidst Nasdaq Delisting Threat and Mounting Losses

A U.S. veterinary hospital operator is seeking to raise up to $5 million through a unit offering to fund working capital and acquisitions, while grappling with significant net losses and a Nasdaq listing deficiency.

Summary

• The Company is offering up to 3,289,473 units, each consisting of one Class A common stock share (or a pre-funded warrant) and one warrant, at an assumed offering price of $1.52 per unit, aiming to raise up to $5 million in gross proceeds.
• The Company received a Nasdaq notice on April 10, 2025, for non-compliance with the minimum stockholders' equity requirement ($1,562,005 as of December 31, 2024), and does not meet market value or net income alternatives, which serves as a basis for delisting.
• The Company reported a net loss of $2,415,036 for the three months ended March 31, 2025, and $14,264,261 for the fiscal year ended December 31, 2024.
• Total revenue decreased by 25% to $3,639,209 for the three months ended March 31, 2025, compared to $4,831,567 for the same period in 2024, primarily due to the divestiture of Kauai Veterinary Clinic (KVC) and reduced DVM capacity.
• The Company completed the acquisition of Debary Animal Clinic on June 5, 2025, for an aggregate purchase consideration of $925,000 (including $832,500 cash and 54,734 restricted Class A common shares) and related real estate for $1,132,000 cash.
• New promissory notes were issued to 1800 Diagonal Lending LLC ($204,700 principal) and Boot Capital LLC ($92,000 principal) on May 30, 2025, for general working capital, with high effective interest rates and conversion rights for lenders upon default.
• Two additional promissory notes were issued to Target Capital LLC on June 10, 2025 ($600,000 principal, $500,000 purchase price) and June 30, 2025 ($625,000 principal, $500,000 purchase price), also for general working capital, with a clause requiring 50% of net proceeds from any capital raise to repay these notes.
• The Company's independent auditors included an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The company is facing significant financial challenges, including recurring losses, negative working capital, and a Nasdaq listing deficiency, raising substantial doubt about its ability to continue as a going concern. While it is actively pursuing acquisitions and capital raises, the current financial state and high-interest debt indicate a precarious position.

Positives

• Successfully completed the acquisition of Debary Animal Clinic, expanding its network to fourteen hospitals across nine states.
• Strategic focus on acquiring existing, financially tracked hospitals with growth potential, leveraging a distributed leadership and support structure.
• Diversification of services into equine care and plans for future expansion into emergency and mixed animal facilities.
• Management believes its personalized approach to purchasing and integrating hospitals, along with a broad employee equity offering, differentiates it from larger competitors.
• Established contacts with major veterinary brokerages provide a pipeline for future acquisitions.

Negatives

• Reported a net loss of $2,415,036 for the three months ended March 31, 2025, and $14,264,261 for the fiscal year ended December 31, 2024.
• Received a Nasdaq listing deficiency notice on April 10, 2025, due to stockholders' equity of $1,562,005 falling below the minimum requirement, risking delisting.
• Total revenue decreased by 25% for the three months ended March 31, 2025, compared to the same period in 2024, with service revenue declining by 23% and product revenue by 30%.
• Independent auditors raised substantial doubt about the Company's ability to continue as a going concern.
• Accumulated deficit of $38,765,317 and negative working capital of $4,570,734 as of March 31, 2025.
• Incurred high effective interest rates on recent short-term financing arrangements, including merchant cash advances (49% and 43%) and original issue discount notes.

Risks

• Limited operating history and may never become profitable, with recurring net losses.
• Inability to attract and retain senior management could negatively impact operations and financial results.
• Need to raise additional capital, which may result in significant dilution to shareholders or the imposition of restrictive debt covenants.
• Significant increased expenses and administrative burdens associated with being a public company.
• Failure to effectively manage growth and integrate acquisitions could materially adversely affect the business.
• Acquisitions may be unsuccessful, and could adversely dilute ownership.
• Ability to utilize net operating loss carryforwards for tax purposes may be limited by future taxable income or Section 382 rules.
• Management's limited experience as senior management of a public company may divert attention from day-to-day operations.
• Failure to maintain effective internal controls over financial reporting could harm business, operating results, and stock price.
• Potential successor liabilities from conduct arising prior to the completion of various acquisitions.
• Purchasing real estate with hospital acquisitions adds complexity and cost due to building inspections, zoning, and permitting.
• Estimates of the addressable market size may prove inaccurate, leading to lower-than-anticipated future growth.
• Difficulties in recruiting and retaining skilled veterinarians due to industry shortages could disrupt business.
• Negative publicity from claims of improper animal care could adversely affect public perception, sales, and profitability.
• Quarterly operating results may fluctuate significantly due to timing of expenses, acquisitions, and closures.
• Reputation and business may be harmed if computer network security or databases containing sensitive information are compromised.
• The animal health industry is highly competitive, with larger competitors possessing greater financial and infrastructure resources.
• Inability to adequately protect intellectual property rights could adversely affect the business.
• Exposure to litigation, which can be expensive, time-consuming, and divert management's attention.
• Natural disasters and other events beyond control could harm business operations and financial condition.
• Various government regulations could limit or delay the ability to develop and commercialize services or negatively impact the business.
• Failure to comply with governmental regulations or the enactment of new laws could lead to fines, litigation, or inability to offer services in certain states.
• Potential failure to comply with state or federal regulations covering the dispensing of prescription pet medications, including controlled substances.
• Subject to environmental, health, and safety laws and regulations that could result in costs.
• Nasdaq listing deficiency notice and the risk of delisting, which could lead to limited market quotations, reduced liquidity, and decreased ability to raise future capital.
• Uncertainty regarding the actual number of shares sold and gross proceeds from the purchase agreement with Tumim Stone Capital LLC.
• Investors who buy shares at different times may pay different prices and experience varying levels of dilution.
• Lack of research coverage by securities or industry analysts, or adverse opinions, could cause stock price and trading volume to decline.
• No intention to pay cash dividends for the foreseeable future, meaning investment return depends solely on stock price appreciation.
• Shares are subordinate to all debts and liabilities, increasing the risk of losing the entire investment in liquidation.
• The board of directors may designate and issue new classes of stock (e.g., Class B with 25 votes per share) that could adversely affect Class A common stock holders, with non-independent directors controlling approximately 98.0% of voting power.
• The trading price of Class A common stock is volatile, which could result in substantial losses to investors.
• Sales of a significant number of Class A common stock shares in the public markets, or the perception of such sales, could depress the market price.
• Reduced disclosure requirements as an emerging growth company and smaller reporting company may make Class A common stock less attractive to investors.
• Warrants and Pre-Funded Warrants are speculative in nature, with no established public trading market for them.
• The Company will not receive any meaningful additional funds upon the exercise of the Pre-Funded Warrants.
• The market price of Class A common stock may never exceed the exercise price of the Warrants.
• Additional stock offerings in the future may dilute then-existing shareholders' percentage ownership.
• Management will have broad discretion over the use of offering proceeds and may not use them effectively.

Future Outlook

The Company expects to continue incurring net losses for the foreseeable future as it develops and acquires veterinary hospitals. It plans to acquire five to ten units per year, focusing on existing hospitals, and expanding into mixed animal and specialty care. Future expenditures include acquisition costs, regulatory approvals, and marketing. The Company will need additional capital to fund business development and anticipates raising funds through debt or equity financing.

Management Comments

• The Company believes the breakdown of gross revenue into service revenue and product revenue categories produces meaningful measures to Company management and the Company's investors in light of the Company's objective to protect the service channel and derive the majority of its revenue from services and expertise which are not capable of disruption from other channels.
• The Company believes these analyses helps the Company ensure that its caseload is revenue positive to avoid clinicians spending time on patient work which underutilizes their time and erodes labor profitability.
• Management believes our continued success is largely dependent on positive perceptions of our company as a high-quality employer and operator within the veterinary space.
• Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

Industry Context

The pet care industry is highly fragmented, with over 28,000 veterinary hospitals in the U.S. and less than 25% consolidated. Competitors range from large national consolidators (e.g., Mars, NVA, Pathway/Thrive, VetCor) to regional groups. The Company aims to differentiate itself through a broad employee equity offering, a personalized acquisition and integration approach that allows acquired locations to sustain their identities, customized coaching for clinicians, and a conservative valuation process focused on long-term Return On Investment.

Comparison to Industry Standards

• The Company aims for 70% to 80% of gross revenue from services, which aligns with generally accepted industry target metrics for veterinary service providers.
• The Company utilizes Revenue Per Patient Per day (RPP) and Average Patient Charge (APC) metrics to analyze the comprehensive nature of diagnostics and services, which are considered 'quality medicine metrics' within the veterinary service industry.
• The Company's acquisition valuation process is based on a 3-year look back and conservative enterprise values, designed to support long-term Return On Investment, which contrasts with some competitors' reliance on trailing twelve measures or buying at inflated multiples of EBITDA or revenue.
• The Company's valuation of client lists uses an industry standard retention rate of 74%, which is noted as a relatively small value allocation compared to goodwill, suggesting potential for higher valuation if a higher retention rate (e.g., 80%) were used.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is addressing a situation where a former animal clinic and hospital violated their non-compete agreement post-employment. Legal action has been initiated in Ohio State Court against the former owner, and the Company anticipates a favorable judgment, likely resulting in compensation below a certain threshold.
• As of the prospectus date, neither the Company nor any of its subsidiaries is a party to any other pending legal proceedings, nor are they aware of any such proceedings threatened against them.

Related Party Transactions

• **Blue Heron Consulting (BHC)**: The Company had a consulting agreement with BHC, where Charles Stith Keiser (a director) is COO and Dr. Charles Chuck Keiser (a director) is Chief Visionary Officer. The service agreement was terminated in Q4 2023, but the Company continues to use BHC for ad hoc services, incurring $49,043 in Q1 2025 and $68,027 in Q1 2024.
• **Star Circle Advisory Group, LLC**: The Company had a consulting agreement with Star Circle, owned and controlled by Kimball Carr (CEO) and former directors. This agreement was terminated in Q4 2023, with no expenses incurred in Q1 2025 or Q1 2024.
• **Chief Executive Officer's Warrant**: On January 1, 2023, 500 warrants for Class A common stock were issued to Kimball Carr (CEO) in consideration for his personal guaranty of Company loans.
• **Sale of Kauai Veterinary Clinic (KVC)**: On September 20, 2024, KVC was sold to Kauai RE Holdings LLC. Gregory Armstrong, a current shareholder, was the agent. Charles Keiser, DVM (father of director Charles Stith Keiser, who controls Wilderness Trace Veterinary Partners, LLC, the largest shareholder), is a member of Kauai RE.
• **FSB Commercial Loans**: Certain commercial loans from First Southern National Bank (FSB) are guaranteed by Kimball Carr (CEO & President) and Charles Stith Keiser (Director and former COO).

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from current and future equity offerings, potential delisting from Nasdaq, stock price volatility, and subordination of shares to debt. The concentrated voting power of non-independent directors limits the influence of other shareholders.
• **Employees**: May experience difficulties in recruiting and retaining skilled veterinarians due to industry shortages. The Company offers a broad equity offering through an Employee Stock Option Plan.
• **Customers**: Could be impacted by operational disruptions, potential changes in service quality due to staffing issues, or negative publicity regarding animal care practices.
• **Creditors**: Face higher risk due to the Company's recurring losses, negative working capital, and the auditors' substantial doubt about its going concern ability. Debt is secured by virtually all company assets, and some recent financing carries very high effective interest rates.
• **Suppliers**: While not explicitly detailed, the Company's financial health and liquidity challenges could indirectly affect its ability to maintain favorable terms with suppliers.

Next Steps

• Regain compliance with Nasdaq's minimum stockholders' equity requirement to avoid delisting.
• Continue to seek additional funding through debt or equity financing to support operations and growth.
• Identify and acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.
• Expand service offerings and build out digital and data capabilities.
• Grow market share in services like grooming and training, and enhance the owned brand portfolio.
• Potentially expand the mergers and acquisitions team to facilitate faster growth.
• Implement tele-veterinarian services, which will require significant information technology investments.
• Continue legal action against a former employee for violating a non-compete agreement.

Key Dates

Recommendation

Keywords

veterinary services, animal health, pet care, veterinary hospitals, acquisitions, Nasdaq listing, S-1 filing, public offering, equity raise, debt financing, financial performance, risk factors, corporate governance, small animal practice, equine care, pre-funded warrants, common stock, dilution, going concern